China RNA Activation Venture Ractigen Looks To Clinic For Validation
Executive Summary
A China returnee CEO has raised roughly $50m for his bioventure that is looking to clinically validate and commercialize an RNA activation platform he co-discovered while working in the US.
You may also be interested in...
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Explained: How China’s Public Payer Wants To Define Innovative Drugs
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter revealed during a recent industry event. The disclosure has unnerved pharma companies, which have been hit by sharp drug price discounts that were required by the public payer in exchange for reimbursement coverage.
China Biotech Podcast: BIOSECURE Updates, Genmab/ProfoundBio Deal
In this mixed Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Pashadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed BIOSECURE Act in the US Congress and US-China biotech movements. Also discussed is how Chinese biotechs are becoming acquisition targets for overseas biotech companies, including the recent purchases of Profound by Genmab and AnHeart Theraputics by Nuvantion.